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Abstract
Oxytocin (OT) and Oxytocin receptor signaling mechanism had emerged as 
a pathway for treatment of metabolic disorders like obesity, and diabetes. Both 
agonists and antagonists activity of the oxytocin receptor has beneficial aspects. 
This chapter will outline the receptor agonists and antagonist’s activity as a function 
of the features: hydrophobic regions, activity shapes, and positive and negative 
electrostatics. Also, their phenotype characteristics in various diseases like diabe-
tes, obesity, cardiovascular and immune related diseases will be outlined. Finally, 
therapeutic development strategies for using various nanomaterials, and other 
biomaterials, as well as those in present use will be discussed.
Keywords: oxytocin, agonists and antagonists, drug delivery, nanomaterials, 
biomaterials, diabetes, obesity, regenerative medicine
1. Introduction
Oxytocin (OT) was the first hormone to have its composition determined and 
was synthesized in a biologically active manner [1]. OT is a major neuropeptide, 
and its roles involve control of neuroendocrine reflexes [2], the development of par-
ticular social and bonding habits [3], and the reproductive and maternal functions 
[4]. Cyclic nonapeptide OT and its structurally related peptides facilitate reproduc-
tion in many vertebrates.
In earlier years, OT was believed to be restricted to stimulate uterine con-
tractions during childbirth [5] and milking (lactation) but the fact that OT is 
found in both men and women in the brain and plasma indicates there are other 
 significant roles.
Most of the OT like peptides are nonapeptides and have a disulfide bridge 
between cysteine residues 1 and 6. The residue Lysine at position 3 and arginine 
or lysine at position 8 are responsible for biological activity of oxytocin peptide, 
that is, to activate oxytocin receptor [1]. Generally, the nonapeptides are classified 
as vasopressins and OT families, and are based on the presence of basic amino 
acid at position 8 and neutral amino acids. Figure 1 shows the phylogenetic tree 
 corresponding to oxytocin like peptides, retrieved from Uniprot webpage [6].
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The oxytocin gene is located on chromosome 3p25 and comprises 3 introns 
and 4 exons and belongs to the G protein-coupled receptor (GPCR) superfamily. 
Oxytocin binds to receptors that activate intracellular signaling pathways, trig-
gering the activation of proteins. Figure 2 was developed by the authors to show 
in a schematic way, the oxytocin-oxytocin receptor (OT-OTR) signaling pathway 
in the body. Upon binding OT to OTR, Gq/phospholipase C (PLC)/inositol 
Figure 2. 
Molecular features of oxytocin receptor modulators calculated using forge tool. Oxytocin receptor linked 
signaling pathways resulting in cell phenotype. OT: Oxytocin, OTR: Oxytocin receptor, PLC: Phospholipase, 
PIP2: Phosphatidylinositol 4,5-bisphosphate, InsP3: Inositol 1,4,5- triphosphate, DAG: Diacylglycerol, PKC: 
Protein kinases type C, MLC: Myosin light-chain, MAPK: Mitogen-activated protein kinase, cPLA2: Cytosolic 
phospholipase A2, ROK: RhoA associated protein kinase.
Figure 1. 
Phylogenetic tree of oxytocin like peptides. Oxytocin like peptides are denoted using their Uniprot ID (Uniprot 
webpage [6]).
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1,4,5-triphosphate (InsP3) pathway dominates the phosphatidylinositol 4,5-bispho-
sphate (PIP2) hydrolysis and this results in InsP3 and diacylglycerol (DAG) (DAG). 
InsP3 releases Ca2+ ions from the intracellular sarcoplasmic reticulum stores, but 
the DAG further activates protein kinases which phosphorylate other proteins. 
Mammary epithelial cells and milk ejection is caused by Ca2+ ions. Activation of 
MAPK cascade is triggered by OTR and PKC resulting in increased expression of 
cPLA2 activity, which eventually results in development of prostaglandins. The 
profusion of prostaglandins development often causes muscle contractions. OTR 
activation elicits phosphorylation of calcineurin. All these signaling pathways result 
in many cellular effects such as cell formation, cell differentiation, and motility.
Transmembrane domains 3,4, and 6 of oxytocin receptor forms the docking site 
to oxytocin peptide cyclic part, and other c terminal domain of oxytocin interacts 
closely with domain 2 and domain 3 in the extracellular space of the oxytocin recep-
tor. The key OTR residues R34, F103, D85, F284, and Y209, play a role in selectiv-
ity of oxytocin peptide. Based on the activity of oxytocin receptor, the oxytocin 
analogues were classified as agonists and antagonists.
2. OTR agonists and antagonists
Receptor binding and functional studies were generally used to identify oxyto-
cin receptor agonists and antagonist activity. There are more than thousand com-
pounds in literature as OTR agonists and antagonists, and this section was focused 
to demonstrate the applicability of molecular shape features as tool to develop 
agonists and antagonists. For this reason, peptide agonist and antagonist molecular 
shapes features are compared with oxytocin.
Substitution of hydoxyl group at position 1 and threonine at position 4 of original 
oxytocin peptide (peptide 1, Figure 3) revealed highest affinity to oxytocin receptor 
(OTR), with value of Ki 0.31 nM and served as oxytocin agonist and as a possible 
treatment of autism [7], and for the treatment of postpartum hemorrhage [8]. 
Figure 3. 
Molecular features of oxytocin receptor modulators calculated using forge tool.
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Peptide atosiban (peptide 2, Figure 3) revealed affinity to oxytocin receptor with a 
value of Ki 76 nM, and it is used in clinical as oxytocin antagonist [9]. Newly devel-
oped Cresset XED force field provided by software Forge [10] was utilized to under-
stand the key features of oxytocin, agonist and antagonist of oxytocin receptor.
Figure 3 was developed by the authors using Forge tool for oxytocin, agonist and 
antagonist of OTR, and features were visualized using Forge visualization software 
to show the comparison of features: red color (positive electrostatics), blue color 
(negative electrostatics), and gold color (hydrophobic shapes).
The molecular features shown in Figure 3 are the result of activities and clearly 
reveal agonist and antagonist function on the oxytocin receptor. Visual examination 
either manually or using imaging algorithms of all the fields, reveals the presence 
of positive electrostatic feature in definite coordinates, and size and shape are 
responsible for agonist and antagonist activity of OTR. Increased electronegative 
regions favor agonist activity, and similarly, hydrophobic shape features are distinct 
for agonist and antagonist activity of OTR. The features mentioned in this study, 
indeed can be utilized by various investigators to discover, develop, and optimize 
agonist and antagonists of OTR. It is well possible to screen various libraries and 
chose the molecules of interest.
3. Phenotype characteristics in various diseases
Oxytocin receptor agonists and antagonists has potential benefits in health 
care, especially in treating diabetes, obesity, cardiovascular, and immune related 
disorders. It is well known that diabetes is considered one of the major causes of 
mortality and a metabolic disorder. Incidence of diabetes mellitus will increases 
over coming decades and is generally considered that affect many organs [11]. 
Many researchers has demonstrated beneficial effect of oxytocin, as endogenous 
factor, with significant changes in insulin sensitivity [12], lipidomic [13], and 
glucose metabolism [14]. Oxytocin stimulates glucose uptake [14, 15], and glucagon 
secretion [16] in pancreatic islets which is directly implicated in improvement and 
involvement of pathophysiology of diabetes.
Apart from diabetes, another major problem most of countries are concerned 
about is obesity, both in Mexico and worldwide [17, 18]. Oxytocin is well known 
for its effects in control of the energy balance [19]. It’s well proven that oxytocin 
administration reduces body weight [20], food intake [21], and glucose tolerance 
was observed with administration of oxytocin [22]. In addition, oxytocin admin-
istration induces a marker of neuronal activation that is known as Fos [23], that is 
linked to control meal size, regulation of intake of food and indeed bodyweight.
Another class of disease is cardiovascular disease, where 13% of deaths are due 
to this, specifically due to blood pressure, followed by tobacco, diabetes, and lack 
of exercise [24]. Cardiovascular diseases involve generally blood vessels or heart 
[25]. Oxytocin receptor decreases blood pressure [26] and lowers brain natriuretic 
peptide [27]. Oxytocin was also proven to facilitate the recovery of cardiovascular 
system (CVS) [28] from injuries [29] and decrease progression of atherosclerosis. 
Key pathways involved in cardiovascular protection upon treatment with oxytocin 
act by suppressing the increasing production of cytokines, apoptotic pathways are 
activated through the involvement of multiple signaling pathways [29].
Oxytocin is also involved in immune related health problem; oxytocin was 
proven to trigger thymocyte proliferation [30], inducing immune tolerance, which 
is generally observed in thymus which is a primary tissue responsible for [31]. The 
nonapeptide oxytocin interacts with neurohypophysial peptide receptors expressed 
by pre-T cells and induces phosphorylation of focal adhesion kinase [32]. Generally, 
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oxytocin production decreases with age, which is linked to thymic involution. 
Oxytocin also has antiviral activity and it has been reported its possible used to treat 
CoVID-19 through DPP-inhibition mechanism of action [33, 34].
4.  Nano, micro and macro materials for delivery of agonists and 
antagonists
Up today, oxytocin receptor agonists and antagonists formulations including 
nano, micro and macro materials are not available in the market. Existing oxyto-
cin receptor agonists and antagonists possess drawbacks like lack of efficacy, no 
improvement in neonatal outcomes, low stability, short half-life in-vivo, and low 
bioavailability.
Many researchers had started to utilize alternative approaches to address men-
tioned drawbacks, and among these, encapsulations for slow and steady oxytocin 
release are under investigation. Most of them are polymeric carriers, and liposome-
based technologies.
Among the polymeric carriers for oxytocin, solvent displacement method was 
utilized to synthesize poloxamer hydrogel scaffold, to encapsulate oxytocin in 
hydrogel graft constituted of poly(d, l-lactide-co-glycolide) (PLGA), β-tricalcium 
phosphate, and hydroxyapatite (CP). This method yielded 89.5% encapsulation 
efficiency, slowly release encapsulated oxytocin, and finally yielded significant 
regeneration of bone loss in rat calvaria [35].
Another nanomaterial application was based on Bovine Serum Albumin (BSA) 
based nanocomposites. It is a twostep process to synthesize nanocomposites, 
nanoprecipitation followed by lyophilization. Transferrin (Tf) and Rabies Virus 
Glycoprotein (RVG) was conjugated to synthesized oxytocin-BSA nanoparticles for 
successful delivery of oxytocin across blood brain barrier (BBB). This composite 
was delivered intranasally, and an improvement in oxytocin bioavailability was 
observed. Delivery of oxytocin using nanocomposites led to greater pro-social 
effects in comparison to oxytocin alone within 3 days of intranasal administration. 
This delivery system definitely benefits social-deficit disorders and indeed enhance 
the brain delivery peptides [36].
Another important nanocarrier utilized in successful delivery oxytocin receptor 
agonists and antagonists is liposomal drug delivery systems. In specific, antibody-
based liposomes were applied where PEGylated liposomes were conjugated 
with atosiban (ATO-Lipo, OTR antagonist) or anti-OTR monoclonal antibodies 
(OTR-Lipo) using the technology of dried lipid film hydration. This method 
increased intracellular internalization, and revealed that the cellular uptake is 
dependent on caveolin-mediated mechanisms, with no cellular toxicity observed. 
Antibody-conjugated liposomes gave way to improved treatment for obstetric 
 complications [37].
5. Future perspectives
Since the therapeutic effects of agonists and antagonists are growing, more 
studies will be needed to protect them against biodegradation, to increase intestinal 
absorption particularly with use of technologies, such as enhancer absorption 
(cyclodextrines), surfactants, cell penetration peptide, chemistry modifications, 
nano, micro and macromaterials.
Besides improving drug delivery methods, additional cell-based experiments 
are required to understand the role of oxytocin such as the use of fluorescent tags 
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(HaloTag) to monitor new functions for agonists or antagonists, the use of imaging 
techniques to classify and develop imaging biomarkers is needed to explore the abil-
ity of oxytocin receptor agonists or antagonists across tissues, cell-host interactions. 
In addition, the molecular features described in this study can be used to discover 
new and novel oxytocin receptor agonists and antagonists.
6. Conclusion
Molecular shape features of oxytocin receptor agonist and antagonist activity as 
a function of positive and negative electrostatic, and hydrophobic shapes features 
were developed and detailed. Also, liposome and polymeric based strategies in 
improving most of the drawbacks associated with oxytocin delivery were discussed. 
More studies are needed towards the application of diverse nanomaterials to deliver 
neuropeptides and improve their efficacy. Some of the tools proposed in this chap-
ter can guide the future research in improving the delivery strategies of oxytocin 
receptor agonists and antagonists.
It has to be remembered that, technologies need to be developed for each route 
of administration, maintain stability, and steady state release of encapsulated active 
ingredients.
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